Skip to main
  1. Stocks
  2. ADC Therapeutics
  3. Forecast
ADCT

ADC Therapeutics (ADCT) Stock Forecast & Price Target

ADC Therapeutics (ADCT) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

ADC Therapeutics is supported by ZYNLONTA’s commercial approval, which reduces regulatory risk and provides tangible cash flows, while its demonstrated efficacy strengthens physician adoption and the potential for broader use across indications. The company also has optionality in additional indolent lymphomas, and the cited capital raise in 4Q25 gives it a cash runway until 2028, which appears sufficient to fund execution of its likely expansion into earlier lines of treatment. With the U.S. as the largest revenue contributor and Europe, the Middle East and Africa next, the geographic footprint adds further commercial leverage to the positive outlook.

Bears say

ADC Therapeutics is facing a weaker fundamental profile because ZYNLONTA’s confirmatory LOTIS-5 data showed only a modest PFS gain (HR 0.73) with no OS benefit (HR 0.96) and an elevated Grade 5 TEAE rate, prompting FDA “substantial concerns” about benefit-risk and verification of clinical benefit. The company’s 2Q net sales of $18.6M were only stable rather than accelerating, and while it ended the quarter with $219M in cash and said runway extends at least into 2028, that liquidity cushion does not offset the growing regulatory overhang or the risk that 2L+ DLBCL adoption remains limited. Although management outlined a $10M annualized cost reduction and continued development plans for LOTIS-7 and other programs, the stock faces reduced approval probability, slower revenue ramp assumptions, and a more uncertain competitive position in a crowded lymphoma market.

ADC Therapeutics (ADCT) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ADC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

ADC Therapeutics (ADCT) Analyst Forecast & Price Prediction

Get the latest ADC Therapeutics (ADCT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ADC Therapeutics (ADCT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ADC Therapeutics (ADCT) Forecast

Analysts have given ADC Therapeutics (ADCT) a Buy based on their latest research and market trends.

According to 3 analysts, ADC Therapeutics (ADCT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ADC Therapeutics (ADCT)


ADC Therapeutics (ADCT) Analyst Forecast & Price Prediction

Get the latest ADC Therapeutics (ADCT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ADC Therapeutics (ADCT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ADCT stock data and trends